Issue 17: May 14 2016 – Read the complete newsletter here.
This issue features…
1. NEW PODCAST IS ONLINE: Lattice’s Approach and New Products for the Future of Biotech
Recently, Stockhouse Publishing Head of Editorial Gaalen Engen sat down with Lattice Biologics Ltd. CEO Guy Cook to discuss: what sets the company apart within the biotech space, its current projects, and how the technology behind their Next Generation Allografts and precision cancer diagnostics work. Listen to the podcast here!
“Through the use of its ECM technology, the Company is developing a disruptive cancer diagnostic technique that is sure to revolutionize the way oncologists treat patients by allowing them to find the best possible anti-cancer drug regimen specific to the patient, without subjecting that patient to the traditional trial-and-error methodology. As a result, significantly increasing the possibility of safe, successful cancer treatment.” – Gaalen Engen, Stockhouse Publishing
2. SPOTLIGHT ON CANCER CARE: Tackling One of Brain Cancer’s Biggest Beasts: Glioblastoma
Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive type of cancer that begins within the brain.
Finding a Foothold: In order to make diagnostic advances against GBM by identifying quick-turnaround chemotherapy regimen recommendations to save time in combatting this rapidly progressing disease without using the patient’s body as a testing ground, it will be important to develop an effective method for growing and sustaining these tumors outside of the body.
Although the Glioblastoma cells reproduce quickly in the body, they are notoriously difficult to grow in a laboratory setting. There is wide support among the scientific and medical communities for the concept that cancerous tumors originate from aberrant stem cells, so it would make sense to utilize our Extracellular Matrix (ECM) technology as a way to mimic the cells’ natural environment and effectively grow these tumors outside of the body.
Lattice Biologics’ ECM is decellularized technology derived from native ECM secreted by human Mesenchymal Stem Cells (hMSC), potentially making it the ideal medium to support natural cancer tumor cell growth in a clinical setting.
3. BIOTECH FUN FACT: History Close to Home: Discovery of the Basis of All DNA Amplification
The Story of Taq: How the discovery of prehistoric microscopic organisms in Yellowstone National Park made viable DNA cloning, sequencing, and analysis possible. The magical Taq polymerase was discovered by Montana State University (MSU) in the natural hot springs created by Yellowstone National Park’s geysers at Yellowstone National Park.
The Incredible Benefits of Taq: Because the Taq polymerase enzyme can withstand extreme temperatures, it proved essential in the artificial replication of DNA for the polymerase chain reaction (PCR) – a process used in molecular biology to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. Taq can replicate a 1000 base pair strand of DNA in less than 10 seconds at 72°C.
“Thus, the use of Taq polymerase was the key idea that made PCR applicable to a large variety of molecular biology problems concerning DNA analysis.” PCR is used in medical and biological research labs for a variety of applications:
- DNA cloning for sequencing
- DNA-based phylogeny, or functional analysis of genes
- Diagnosis of hereditary diseases
- Identification of genetic fingerprints (used in forensic sciences and DNA paternity testing)
- Detection and diagnosis of infectious diseases.
4. INDUSTRY EVENTS: Recent Event Recap and Where to Find Lattice at Upcoming Events
- 2nd Annual CDx Regulation & Reimbursement Summit 2016: Herndon, VA | May 17-19
- 10th World Biomaterials Congress (WBC): Montreal, QC, CA | May 17-22
Click Subscribe to receive updates.
Media Contact: Melanie Battista, Public Relations, Lattice Biologics Ltd., 16701 N 90th Street, Suite #101, Scottsdale, AZ 85260, 480-563-0800 Office, News@LatticeBiologics.com | www.LatticeBiologics.com
Follow us on Twitter: @LatticeBio